C Massard
Overview
Explore the profile of C Massard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charton E, Baldini C, Fayet Y, Schultz E, Auroy L, Vallier E, et al.
ESMO Open
. 2023 Aug;
8(4):101610.
PMID: 37536254
Background: Investigation of the disparities in the access to experimental treatment in early-phase clinical trials is lacking. The objective of the EGALICAN-2 study was to identify the factors underpinning such...
2.
Massard C, Cassier P, Azaro A, Anderson B, Yuen E, Yu D, et al.
Cancer Chemother Pharmacol
. 2022 Aug;
90(4):335-344.
PMID: 36030462
Background: Notch signaling plays an integral role in development and tissue homeostasis. Inhibition of Notch signaling has been identified as a reasonable target for oncotherapy. Crenigacestat (LY3039478) is a potent...
3.
Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen C, Obermannova R, et al.
ESMO Open
. 2022 Aug;
7(5):100562.
PMID: 35987165
Background: The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors. This phase I/II study (NCT03637764)...
4.
Baldini C, Charton E, Schultz E, Auroy L, Italiano A, Robert M, et al.
ESMO Open
. 2022 May;
7(3):100468.
PMID: 35533427
Background: Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related disease because the incidence of most...
5.
Nassif E, Blay J, Massard C, Dufresne A, Brahmi M, Cassier P, et al.
ESMO Open
. 2022 Mar;
7(2):100425.
PMID: 35255445
Background: The prognosis of patients with advanced soft-tissue sarcomas (STS) remains dismal, and systemic therapeutic options are limited. Early phase trials are becoming increasingly safe and effective. This study aimed...
6.
Aldea M, Cerbone L, Bayle A, Parisi C, Sarkozy C, Vasseur D, et al.
Ann Oncol
. 2021 Sep;
32(12):1642-1645.
PMID: 34509616
No abstract available.
7.
Loriot Y, Marabelle A, Guegan J, Danlos F, Besse B, Chaput N, et al.
Ann Oncol
. 2021 Aug;
32(11):1381-1390.
PMID: 34416362
Background: Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a crucial need to identify novel...
8.
Laparra A, Kfoury M, Champiat S, Danlos F, Martin-Romano P, Simonaggio A, et al.
Ann Oncol
. 2021 Apr;
32(7):936-937.
PMID: 33865965
No abstract available.
9.
Mir O, Watson S, Massard C, Le Cesne A, Benhadji K, Soria J
Ann Oncol
. 2020 Sep;
31(12):1782-1784.
PMID: 32941988
No abstract available.
10.
Henon C, Blay J, Massard C, Mir O, Bahleda R, Dumont S, et al.
Ann Oncol
. 2019 May;
30(8):1401-1403.
PMID: 31114851
No abstract available.